Sirion Therapeutics Initiates Enrollment Of Phase III Clinical Trials For The Treatment Of Inflammation Following Ocular Surgery
Tue, 23 Jan 2007 08:00 AM EST
... Sirion Therapeutics, Inc., an ophthalmic-focused biopharmaceuticals company, announced today that it has begun enrollment of two phase III clinical trials, which will evaluate ST-601 (difluprednate) in the treatment of inflammation following ocular surgery. [click link for full article] ...
Related Topics
- Clinical Trials
- Pharmacology
- Antithrombin III
- Histoplasmosis
- Surgery
- Lasik Eye Surgery
- Plastic and Cosmetic Surgery
- Psychopharmacology
- Cataracts
- Cataract
- Cholangitis (inflammation of a bile duct), cholecystitis (inflammation of the gallbladder)
- Familial Dysautonomia
- Heart Bypass Surgery
- Bunion
- Cosmetic
- Toe Injuries and Disorders
- Esophagus
- Western/Clinical Treatment and Therapy
- Depression
- Food Recommendations: South Beach Diet - Phase 2

Not Signed In -

